A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts

Gaurav Swarnkar, Kunal Sharan, Jawed A. Siddiqui, Jay Sharan Mishra, Kainat Khan, Mohd Parvez Khan, Varsha Gupta, Preeti Rawat, Rakesh Maurya, Anil K. Dwivedi, Sabyasachi Sanyal, Naibedya Chattopadhyay

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE Naringenin and its derivatives have been assessed in bone health for their oestrogen-'like' effects but low bioavailability impedes clinical potential. This study was aimed at finding a potent form of naringenin with osteogenic action. EXPERIMENTAL APPROACH Osteoblast cultures were harvested from mouse calvaria to study differentiation by naringenin, isosakuranetin, poncirin, phloretin and naringenin-6-C-glucoside (NCG). Balb/cByJ ovariectomized (OVx) mice without or with osteopenia were given naringenin, NCG, 17β-oestradiol (E2) or parathyroid hormone (PTH). Efficacy was evaluated by bone microarchitecture using microcomputed tomography and determination of new bone formation by fluorescent labelling of bone. Plasma levels of NCG and naringenin were determined by HPLC. KEY RESULTS NCG stimulated osteoblast differentiation more potently than naringenin, while isosakuranetin, poncirin or phloretin had no effect. NCG had better oral bioavailability than naringenin. NCG increased the mRNA levels of oestrogen receptors (ERs) and bone morphogenetic protein (an ER responsive gene) in vivo, more than naringenin. In OVx mice, NCG treatment in a preventive protocol increased bone formation rate (BFR) and improved trabecular microarchitecture more than naringenin or E2. In osteopenic mice, NCG but not naringenin, in a therapeutic protocol, increased BFR and improved trabecular microarchitecture, comparable with effects of PTH treatment. Stimulatory effects of NCG on osteoblasts were abolished by an ER antagonist. NCG transactivated ERβ but not ERα. NCG exhibited no uterine oestrogenicity unlike naringenin. CONCLUSIONS AND IMPLICATIONS NCG is a potent derivative of naringenin that has bone anabolic action through the activation of osteoblast ERs and exhibited substantial oral bioavailability.

Original languageEnglish (US)
Pages (from-to)1526-1542
Number of pages17
JournalBritish Journal of Pharmacology
Volume165
Issue number5
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Anabolic Agents
Osteoblasts
Estrogens
Bone and Bones
Osteogenesis
Phloretin
Biological Availability
Parathyroid Hormone
naringenin-6-C-glucoside
naringenin
X-Ray Microtomography
Bone Morphogenetic Proteins
Metabolic Bone Diseases
Skull
Estrogen Receptors
Estradiol

Keywords

  • bioavailability
  • bone marrow
  • bone microarchitecture
  • flavanones
  • mineralization
  • oestrogen deficiency
  • osteoblast differentiation
  • osteoporosis
  • parathyroid hormone
  • preclinical development

ASJC Scopus subject areas

  • Pharmacology

Cite this

A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. / Swarnkar, Gaurav; Sharan, Kunal; Siddiqui, Jawed A.; Mishra, Jay Sharan; Khan, Kainat; Khan, Mohd Parvez; Gupta, Varsha; Rawat, Preeti; Maurya, Rakesh; Dwivedi, Anil K.; Sanyal, Sabyasachi; Chattopadhyay, Naibedya.

In: British Journal of Pharmacology, Vol. 165, No. 5, 03.2012, p. 1526-1542.

Research output: Contribution to journalArticle

Swarnkar, G, Sharan, K, Siddiqui, JA, Mishra, JS, Khan, K, Khan, MP, Gupta, V, Rawat, P, Maurya, R, Dwivedi, AK, Sanyal, S & Chattopadhyay, N 2012, 'A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts', British Journal of Pharmacology, vol. 165, no. 5, pp. 1526-1542. https://doi.org/10.1111/j.1476-5381.2011.01637.x
Swarnkar, Gaurav ; Sharan, Kunal ; Siddiqui, Jawed A. ; Mishra, Jay Sharan ; Khan, Kainat ; Khan, Mohd Parvez ; Gupta, Varsha ; Rawat, Preeti ; Maurya, Rakesh ; Dwivedi, Anil K. ; Sanyal, Sabyasachi ; Chattopadhyay, Naibedya. / A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 5. pp. 1526-1542.
@article{666111f05b514ef0a54e91e117743642,
title = "A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts",
abstract = "BACKGROUND AND PURPOSE Naringenin and its derivatives have been assessed in bone health for their oestrogen-'like' effects but low bioavailability impedes clinical potential. This study was aimed at finding a potent form of naringenin with osteogenic action. EXPERIMENTAL APPROACH Osteoblast cultures were harvested from mouse calvaria to study differentiation by naringenin, isosakuranetin, poncirin, phloretin and naringenin-6-C-glucoside (NCG). Balb/cByJ ovariectomized (OVx) mice without or with osteopenia were given naringenin, NCG, 17β-oestradiol (E2) or parathyroid hormone (PTH). Efficacy was evaluated by bone microarchitecture using microcomputed tomography and determination of new bone formation by fluorescent labelling of bone. Plasma levels of NCG and naringenin were determined by HPLC. KEY RESULTS NCG stimulated osteoblast differentiation more potently than naringenin, while isosakuranetin, poncirin or phloretin had no effect. NCG had better oral bioavailability than naringenin. NCG increased the mRNA levels of oestrogen receptors (ERs) and bone morphogenetic protein (an ER responsive gene) in vivo, more than naringenin. In OVx mice, NCG treatment in a preventive protocol increased bone formation rate (BFR) and improved trabecular microarchitecture more than naringenin or E2. In osteopenic mice, NCG but not naringenin, in a therapeutic protocol, increased BFR and improved trabecular microarchitecture, comparable with effects of PTH treatment. Stimulatory effects of NCG on osteoblasts were abolished by an ER antagonist. NCG transactivated ERβ but not ERα. NCG exhibited no uterine oestrogenicity unlike naringenin. CONCLUSIONS AND IMPLICATIONS NCG is a potent derivative of naringenin that has bone anabolic action through the activation of osteoblast ERs and exhibited substantial oral bioavailability.",
keywords = "bioavailability, bone marrow, bone microarchitecture, flavanones, mineralization, oestrogen deficiency, osteoblast differentiation, osteoporosis, parathyroid hormone, preclinical development",
author = "Gaurav Swarnkar and Kunal Sharan and Siddiqui, {Jawed A.} and Mishra, {Jay Sharan} and Kainat Khan and Khan, {Mohd Parvez} and Varsha Gupta and Preeti Rawat and Rakesh Maurya and Dwivedi, {Anil K.} and Sabyasachi Sanyal and Naibedya Chattopadhyay",
year = "2012",
month = "3",
doi = "10.1111/j.1476-5381.2011.01637.x",
language = "English (US)",
volume = "165",
pages = "1526--1542",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts

AU - Swarnkar, Gaurav

AU - Sharan, Kunal

AU - Siddiqui, Jawed A.

AU - Mishra, Jay Sharan

AU - Khan, Kainat

AU - Khan, Mohd Parvez

AU - Gupta, Varsha

AU - Rawat, Preeti

AU - Maurya, Rakesh

AU - Dwivedi, Anil K.

AU - Sanyal, Sabyasachi

AU - Chattopadhyay, Naibedya

PY - 2012/3

Y1 - 2012/3

N2 - BACKGROUND AND PURPOSE Naringenin and its derivatives have been assessed in bone health for their oestrogen-'like' effects but low bioavailability impedes clinical potential. This study was aimed at finding a potent form of naringenin with osteogenic action. EXPERIMENTAL APPROACH Osteoblast cultures were harvested from mouse calvaria to study differentiation by naringenin, isosakuranetin, poncirin, phloretin and naringenin-6-C-glucoside (NCG). Balb/cByJ ovariectomized (OVx) mice without or with osteopenia were given naringenin, NCG, 17β-oestradiol (E2) or parathyroid hormone (PTH). Efficacy was evaluated by bone microarchitecture using microcomputed tomography and determination of new bone formation by fluorescent labelling of bone. Plasma levels of NCG and naringenin were determined by HPLC. KEY RESULTS NCG stimulated osteoblast differentiation more potently than naringenin, while isosakuranetin, poncirin or phloretin had no effect. NCG had better oral bioavailability than naringenin. NCG increased the mRNA levels of oestrogen receptors (ERs) and bone morphogenetic protein (an ER responsive gene) in vivo, more than naringenin. In OVx mice, NCG treatment in a preventive protocol increased bone formation rate (BFR) and improved trabecular microarchitecture more than naringenin or E2. In osteopenic mice, NCG but not naringenin, in a therapeutic protocol, increased BFR and improved trabecular microarchitecture, comparable with effects of PTH treatment. Stimulatory effects of NCG on osteoblasts were abolished by an ER antagonist. NCG transactivated ERβ but not ERα. NCG exhibited no uterine oestrogenicity unlike naringenin. CONCLUSIONS AND IMPLICATIONS NCG is a potent derivative of naringenin that has bone anabolic action through the activation of osteoblast ERs and exhibited substantial oral bioavailability.

AB - BACKGROUND AND PURPOSE Naringenin and its derivatives have been assessed in bone health for their oestrogen-'like' effects but low bioavailability impedes clinical potential. This study was aimed at finding a potent form of naringenin with osteogenic action. EXPERIMENTAL APPROACH Osteoblast cultures were harvested from mouse calvaria to study differentiation by naringenin, isosakuranetin, poncirin, phloretin and naringenin-6-C-glucoside (NCG). Balb/cByJ ovariectomized (OVx) mice without or with osteopenia were given naringenin, NCG, 17β-oestradiol (E2) or parathyroid hormone (PTH). Efficacy was evaluated by bone microarchitecture using microcomputed tomography and determination of new bone formation by fluorescent labelling of bone. Plasma levels of NCG and naringenin were determined by HPLC. KEY RESULTS NCG stimulated osteoblast differentiation more potently than naringenin, while isosakuranetin, poncirin or phloretin had no effect. NCG had better oral bioavailability than naringenin. NCG increased the mRNA levels of oestrogen receptors (ERs) and bone morphogenetic protein (an ER responsive gene) in vivo, more than naringenin. In OVx mice, NCG treatment in a preventive protocol increased bone formation rate (BFR) and improved trabecular microarchitecture more than naringenin or E2. In osteopenic mice, NCG but not naringenin, in a therapeutic protocol, increased BFR and improved trabecular microarchitecture, comparable with effects of PTH treatment. Stimulatory effects of NCG on osteoblasts were abolished by an ER antagonist. NCG transactivated ERβ but not ERα. NCG exhibited no uterine oestrogenicity unlike naringenin. CONCLUSIONS AND IMPLICATIONS NCG is a potent derivative of naringenin that has bone anabolic action through the activation of osteoblast ERs and exhibited substantial oral bioavailability.

KW - bioavailability

KW - bone marrow

KW - bone microarchitecture

KW - flavanones

KW - mineralization

KW - oestrogen deficiency

KW - osteoblast differentiation

KW - osteoporosis

KW - parathyroid hormone

KW - preclinical development

UR - http://www.scopus.com/inward/record.url?scp=84863395344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863395344&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01637.x

DO - 10.1111/j.1476-5381.2011.01637.x

M3 - Article

C2 - 21864313

AN - SCOPUS:84863395344

VL - 165

SP - 1526

EP - 1542

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 5

ER -